Q4 2024
Released May 29, 2024, after the close
10-K filed May 29, 2024, 59 days after period end · 0001764013-24-000109
Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$75.32M-$75.32M derivedN/M vs Q4 2023N/M vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Cash Flowderived-$59,699,000N/M
Free Cash Flowderived-$59,849,000N/M
What the release said
The release
Same quarter
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2018 |
|---|---|---|---|---|
| Net Income | -$75.32M | -$59.43M | -$47.17M | -$450.00 |
| EPS Diluted | — | — | — | $0.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR